文献速递母胎医学产科

超声联合循环游离胎儿DNA分析无创诊断胎儿软骨发育不全的最优策略

Optimal non-invasive diagnosis of fetal achondroplasia combining ultrasonography with circulating cell-free fetal DNA analysis.
PubMed 文献 · Ultrasound Obstet Gynecol · 2018-11-28

这项前瞻性多中心研究评估了高分辨率熔解曲线(HRM)联合SNaPshot微测序检测孕妇血中cffDNA对胎儿软骨发育不全的无创产前检测(NIPT)效能,并与影像学或侵入性分子诊断对比。86例高危孕妇和65例低危对照中,NIPT总敏感度和特异度均为1.00(95%CI分别为0.87-1.00和0.96-1.00)。受累胎儿股骨长度在26周起出现关键性缩短。

要点

  • HRM联合SNaPshot微测序检测cffDNA是胎儿软骨发育不全的可靠NIPT方法。
  • 高危孕妇中NIPT总敏感度1.00(95%CI 0.87-1.00),特异度1.00(95%CI 0.96-1.00)。
  • 受累胎儿股骨长度自26周起可出现关键性缩短。

核心结论

  • HRM联合SNaPshot微测序是胎儿软骨发育不全无创产前检测的可靠方法。
  • 将其与超声检查结合纳入常规临床流程,是软骨发育不全无创诊断的有效策略。

研究设计与样本

  • 前瞻性多中心研究,从有胎儿软骨发育不全风险的孕妇及低危对照孕妇血中提取cffDNA。
  • 采用HRM联合SNaPshot微测序检测FGFR3基因两种主要突变之一。
  • 结果与三维计算机断层扫描或出生后检查获得的表型,和/或侵入性操作的分子诊断进行比较。
  • 分析胎儿生物测量(头围和股骨长度),以制定仅在选定病例中提供cffDNA分析诊断软骨发育不全的策略。

主要发现

  • 共收集86份有胎儿软骨发育不全风险孕妇的血样和65份对照血样。
  • NIPT总敏感度为1.00(95%CI 0.87-1.00),总特异度为1.00(95%CI 0.96-1.00)。
  • 受累胎儿股骨长度自26周妊娠起可出现关键性缩短。

关键数值与推荐

  • NIPT总敏感度1.00(95%CI 0.87-1.00),总特异度1.00(95%CI 0.96-1.00)。
  • 受累胎儿股骨长度关键性缩短可自26周妊娠起观察到。

临床怎么用

  • 作者认为HRM联合SNaPshot微测序可作为胎儿软骨发育不全的无创产前检测方法。
  • 作者认为将其纳入常规临床流程并与超声检查联合,是软骨发育不全无创诊断的有效策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the performance of non-invasive prenatal testing (NIPT) for achondroplasia using high-resolution melting (HRM) analysis, and to propose an optimal diagnostic strategy combining ultrasound examination and cell-free fetal DNA (cffDNA) analysis. METHODS: In this prospective multicenter study, cffDNA was extracted from blood of pregnant women at risk for fetal achondroplasia (owing to paternal achondroplasia, previous affected child or suspected rhizomelic shortening) and of pregnant low-risk controls. The presence of either one of the two main fibroblast growth factor receptor 3 gene (FGFR3) mutations was determined using HRM combined with confirmation by SNaPshot minisequencing. Results were compared with phenotypes obtained using three-dimensional computed tomography or postnatal examination, and/or molecular diagnosis by an invasive procedure. Fetal biometry (head circumference and femur length) was analyzed in order to develop a strategy in which cffDNA analysis for diagnosis of achondroplasia is offered only in selected cases. RESULTS: Eighty-six blood samples from women at risk for fetal achondroplasia and 65 from controls were collected. The overall sensitivity and specificity of NIPT were 1.00 (95% CI, 0.87-1.00) and 1.00 (95% CI, 0.96-1.00), respectively. Critical reduction in femur length of affected fetuses could be observed from 26 weeks' gestation. CONCLUSIONS: HRM combined with SNaPshot minisequencing is a reliable method for NIPT for achondroplasia. Its implementation in routine clinical care combined with ultrasonography is an efficient strategy for the non-invasive diagnosis of achondroplasia. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Vivanti AJ, Costa JM, Rosefort A, et al. Optimal non-invasive diagnosis of fetal achondroplasia combining ultrasonography with circulating cell-free fetal DNA analysis. Ultrasound Obstet Gynecol. 2018. PMID: 29380944. doi:10.1002/uog.19018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。